Zacks Investment Research Lowers HUTCHISON CHINA/S (HCM) to Sell
HUTCHISON CHINA/S (NASDAQ:HCM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.
According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “
Several other equities research analysts have also recently weighed in on HCM. BidaskClub upgraded shares of HUTCHISON CHINA/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. ValuEngine cut shares of HUTCHISON CHINA/S from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Deutsche Bank began coverage on shares of HUTCHISON CHINA/S in a research report on Monday, March 4th. They set a “buy” rating and a $26.82 price objective for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $26.82.
A number of large investors have recently bought and sold shares of HCM. Macquarie Group Ltd. acquired a new stake in HUTCHISON CHINA/S in the fourth quarter worth $46,000. Quantamental Technologies LLC acquired a new stake in HUTCHISON CHINA/S in the fourth quarter worth $48,000. Bank of Montreal Can grew its holdings in HUTCHISON CHINA/S by 238.5% in the fourth quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock worth $102,000 after purchasing an additional 3,100 shares during the period. QS Investors LLC acquired a new stake in HUTCHISON CHINA/S in the fourth quarter worth $139,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in HUTCHISON CHINA/S in the fourth quarter worth $154,000. Institutional investors and hedge funds own 16.62% of the company’s stock.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
See Also: Google Finance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.